Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Duygu Bozkaya"'
Bilateral visual acuity decline in males with choroideremia: a pooled, cross-sectional meta-analysis
Publikováno v:
BMC Ophthalmology, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background Choroideremia is a rare inherited retinal disease that leads to blindness. Visual acuity (VA) is a key outcome measure in choroideremia treatment studies, but VA decline rates change with age. An accurate understanding of the natu
Externí odkaz:
https://doaj.org/article/bb7f5a30ed944b959b10182f1d5d5b4b
Publikováno v:
Clinical Drug Investigation
Background and Objective Community-acquired bacterial pneumonia (CABP) affects millions of people each year in the USA. The majority of patients with CABP are treated in the community setting with empirical antimicrobial therapy. Delafloxacin is an a
Publikováno v:
Clinical Ophthalmology (Auckland, N.Z.)
Shaobin Dong,1 Nicole Tsao,2 Qiang Hou,1 Duygu Bozkaya,1 Bart P Leroy3â 5 1Value and Access, Biogen, Cambridge, MA, USA; 2Medical Health Outcomes and Research, Biogen, Cambridge, MA, USA; 3Department of Ophthalmology & Center for Medical Genetic
Publikováno v:
Journal of managed carespecialty pharmacy. 26(6)
Hepatic encephalopathy (HE) is a complication of cirrhosis of the liver causing neuropsychiatric abnormalities. Clinical manifestations of overt HE result in increased health care resource utilization and effects on patient quality of life. While lac
Autor:
Steven Faulkner, Timothy W. Smith, Ryan Clark, Robert A. Gerber, Mark Levenberg, Duygu Bozkaya
Publikováno v:
Journal of Medical Economics. 21:770-777
Background Atopic dermatitis (AD), a chronic inflammatory skin disease, is often treated with topical corticosteroids (TCS) and topical calcineurin inhibitors (TCI). Crisaborole ointment is a non-steroidal, phosphodiesterase 4 inhibitor for the treat
Publikováno v:
Journal of medical economics. 20(3)
The safety and efficacy of disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS) has been established; however, it is not clear which provides optimal value, given benefit-risk profiles and costs.To compare the cost-eff
Autor:
Khajak J. Ishak, Duygu Bozkaya, Ahmad Al-Sabbagh, D.M. Meletiche, Randy Bennett, Alexandra Ward, Shien Guo, Judith A. O'Brien
Publikováno v:
PharmacoEconomics. 27(1):39-53
Objective: The EVIDENCE trial concluded that administering high-dose/high-frequency subcutaneous (SC) interferon-beta-1a (IFNb1a) was more effective in preventing relapses among patients with relapsing multiple sclerosis (MS) than low-dose weekly int
Autor:
Alexandra Ward, Duygu Bozkaya, Jochen Fleischmann, J. Jaime Caro, Dominique Dubois, Rainer Sabatowski
Publikováno v:
Current Medical Research and Opinion. 23:2333-2345
The Osmotic controlled-Release Oral delivery System (OROS) hydromorphone ensures continuous release of hydromorphone over 24 hours. It is anticipated that this will facilitate optimal pain relief, improve quality of sleep and compliance. This simulat
Autor:
Duygu Bozkaya, Winnie W. Nelson, Joseph Menzin, Jeff Schein, Kathleen Lang, Aarti A Patel, Samir H. Mody, Brian Macomson, Gary M. Owens
Publikováno v:
BMC Health Services Research
Background Oral anticoagulation is recommended for stroke prevention in intermediate/high stroke risk atrial fibrillation (AF) patients. The objective of this study was to demonstrate the usefulness of analytic software tools for descriptive analyses
Autor:
Kathleen Lang, Duygu Bozkaya, Aarti A Patel, Brian Macomson, Concetta Crivera, Gary Owens, Samir Mody
Publikováno v:
Circulation: Cardiovascular Quality and Outcomes. 6
Background: Antiplatelet agents are a mainstay for the prevention of subsequent myocardial infarction (MI) or stroke among patients with acute coronary syndrome (ACS). This study analyzed recent pharmacy and medical claims from Medicare, Medicaid, an